21 February 2020
GSK and Immatics partner on cell therapies for cancer
GlaxoSmithKline (GSK) has partnered with Germany-based Immatics Biotechnologies for the development of adoptive cell therapies to treat different cancers.
Focus:
News
-
-
21 February 2020
Favilavir approved as experimental coronavirus drug
Zhejiang Hisun Pharmaceutical’s anti-viral drug Favilavir (Favipiravir) has been approved as an investigational therapy to treat the coronavirus, reported local media.
-
21 February 2020
Coronavirus death toll hits 2,247; China calls for medical workers care
Coronavirus deaths have climbed to 2,247, including 2,236 recorded in Mainland China, as of the end of 20 February. In Hubei province, the total number of deaths stands at 2,144.
-
20 February 2020
Seattle Genetics in-licenses some of Five Prime’s antibodies for $5m
California-based Five Prime Therapeutics has signed a global license agreement with Seattle Genetics regarding a family of monoclonal antibodies for a single solid tumour target.
-
20 February 2020
New 3D coronavirus map to facilitate vaccine design
Researchers from the University of Texas at Austin and the National Institutes of Health (NIH) in the US have created a 3D map of the new coronavirus, which could help...
-
20 February 2020
Study finds new SARS-like coronavirus spreads more like flu
A new study by Chinese researchers found that SARS-CoV-2, the new coronavirus, which is genetically similar to SARS, also a type of coronavirus, acts much more like influenza.
-
20 February 2020
Vifor Pharma and Fresenius Kabi form joint venture in China
Vifor Pharma has formed a strategic alliance with Fresenius Kabi to establish a joint venture in the People’s Republic of China, considered the second-largest pharmaceutical market globally.
-
20 February 2020
Covid-19 deaths increase ten-fold in three weeks, to reach 2,130
Deaths from the novel coronavirus have increased to 2,130, representing a ten-fold surge in three weeks from 30 January when the death toll was 213.
-
20 February 2020
Roche’s Tecentriq gets US priority review for lung cancer
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics license application (sBLA) of Tecentriq (atezolizumab) to treat non-small cell lung cancer (NSCLC).
-
20 February 2020
Serum Institute of India brings Covid-19 vaccine into animal testing
Serum Institute of India has announced that its new Covid-19 vaccine candidate, being developed in collaboration with US-based Codagenix, is now in pre-clinical / animal testing phase.
Close
Close
Close
Go Top